Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions.

Midde NM, Huang X, Gomez AM, Booze RM, Zhan CG, Zhu J.

J Neuroimmune Pharmacol. 2013 Sep;8(4):975-87. doi: 10.1007/s11481-013-9464-6. Epub 2013 May 5.

2.

Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport.

Midde NM, Yuan Y, Quizon PM, Sun WL, Huang X, Zhan CG, Zhu J.

J Neuroimmune Pharmacol. 2015 Mar;10(1):122-35. doi: 10.1007/s11481-015-9583-3. Epub 2015 Jan 22.

3.

Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter.

Sun WL, Quizon PM, Yuan Y, Zhang W, Ananthan S, Zhan CG, Zhu J.

Sci Rep. 2017 Jun 16;7(1):3694. doi: 10.1038/s41598-017-03771-0.

4.

Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter.

Yuan Y, Huang X, Midde NM, Quizon PM, Sun WL, Zhu J, Zhan CG.

ACS Chem Neurosci. 2015 Apr 15;6(4):658-665. doi: 10.1021/acschemneuro.5b00001. Epub 2015 Feb 19.

5.
6.

HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes.

Midde NM, Gomez AM, Zhu J.

J Neuroimmune Pharmacol. 2012 Sep;7(3):629-39. doi: 10.1007/s11481-012-9369-9. Epub 2012 May 5.

7.

Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport.

Quizon PM, Sun WL, Yuan Y, Midde NM, Zhan CG, Zhu J.

Sci Rep. 2016 Dec 14;6:39048. doi: 10.1038/srep39048.

8.

An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporter.

Fraser R, Chen Y, Guptaroy B, Luderman KD, Stokes SL, Beg A, DeFelice LJ, Gnegy ME.

Mol Pharmacol. 2014 Jul;86(1):76-85. doi: 10.1124/mol.114.091926. Epub 2014 Apr 21.

9.
10.

Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter.

Pristupa ZB, McConkey F, Liu F, Man HY, Lee FJ, Wang YT, Niznik HB.

Synapse. 1998 Sep;30(1):79-87.

PMID:
9704884
11.

A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation.

Guptaroy B, Zhang M, Bowton E, Binda F, Shi L, Weinstein H, Galli A, Javitch JA, Neubig RR, Gnegy ME.

Mol Pharmacol. 2009 Mar;75(3):514-24. doi: 10.1124/mol.108.048744. Epub 2008 Dec 19.

12.

Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters.

Guptaroy B, Fraser R, Desai A, Zhang M, Gnegy ME.

Mol Pharmacol. 2011 Mar;79(3):520-32. doi: 10.1124/mol.110.069039. Epub 2010 Dec 13.

13.

Differential effects of Zn2+ on the kinetics and cocaine inhibition of dopamine transport by the human and rat dopamine transporters.

Bjorklund NL, Volz TJ, Schenk JO.

Eur J Pharmacol. 2007 Jun 22;565(1-3):17-25. Epub 2007 Feb 23.

PMID:
17408612
14.

Anomalous dopamine release associated with a human dopamine transporter coding variant.

Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH, Galli A, Blakely RD.

J Neurosci. 2008 Jul 9;28(28):7040-6. doi: 10.1523/JNEUROSCI.0473-08.2008.

15.

The role of human dopamine transporter in NeuroAIDS.

Zhu J, Ananthan S, Zhan CG.

Pharmacol Ther. 2017 Oct 5. pii: S0163-7258(17)30244-9. doi: 10.1016/j.pharmthera.2017.10.007. [Epub ahead of print] Review.

PMID:
28987321
16.

SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking.

Bowton E, Saunders C, Reddy IA, Campbell NG, Hamilton PJ, Henry LK, Coon H, Sakrikar D, Veenstra-VanderWeele JM, Blakely RD, Sutcliffe J, Matthies HJ, Erreger K, Galli A.

Transl Psychiatry. 2014 Oct 14;4:e464. doi: 10.1038/tp.2014.90.

17.

Cyclin-dependent kinase 5 inhibitors: inhibition of dopamine transporter activity.

Price DA, Sorkin A, Zahniser NR.

Mol Pharmacol. 2009 Oct;76(4):812-23. doi: 10.1124/mol.109.056978. Epub 2009 Jul 23.

18.

The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study.

Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM.

Neuroscience. 2009 Apr 10;159(4):1292-9. doi: 10.1016/j.neuroscience.2009.01.024. Epub 2009 Jan 20.

19.

Membrane-permeable C-terminal dopamine transporter peptides attenuate amphetamine-evoked dopamine release.

Rickhag M, Owens WA, Winkler MT, Strandfelt KN, Rathje M, Sørensen G, Andresen B, Madsen KL, Jørgensen TN, Wörtwein G, Woldbye DP, Sitte H, Daws LC, Gether U.

J Biol Chem. 2013 Sep 20;288(38):27534-44. doi: 10.1074/jbc.M112.441295. Epub 2013 Jul 24.

20.

Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux.

Binda F, Dipace C, Bowton E, Robertson SD, Lute BJ, Fog JU, Zhang M, Sen N, Colbran RJ, Gnegy ME, Gether U, Javitch JA, Erreger K, Galli A.

Mol Pharmacol. 2008 Oct;74(4):1101-8. doi: 10.1124/mol.108.048447. Epub 2008 Jul 10.

Supplemental Content

Support Center